Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma.
Publication
, Journal Article
Rossi, EC
Published in: Gynecol Oncol
October 2020
Duke Scholars
Published In
Gynecol Oncol
DOI
EISSN
1095-6859
Publication Date
October 2020
Volume
159
Issue
1
Start / End Page
1 / 2
Location
United States
Related Subject Headings
- Uterine Neoplasms
- Oncology & Carcinogenesis
- Humans
- Female
- EGF Family of Proteins
- Cystadenocarcinoma, Serous
- Cohort Studies
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Rossi, E. C. (2020). Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma. Gynecol Oncol, 159(1), 1–2. https://doi.org/10.1016/j.ygyno.2020.09.003
Rossi, Emma C. “Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma.” Gynecol Oncol 159, no. 1 (October 2020): 1–2. https://doi.org/10.1016/j.ygyno.2020.09.003.
Rossi EC. Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma. Gynecol Oncol. 2020 Oct;159(1):1–2.
Rossi, Emma C. “Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma.” Gynecol Oncol, vol. 159, no. 1, Oct. 2020, pp. 1–2. Pubmed, doi:10.1016/j.ygyno.2020.09.003.
Rossi EC. Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma. Gynecol Oncol. 2020 Oct;159(1):1–2.
Published In
Gynecol Oncol
DOI
EISSN
1095-6859
Publication Date
October 2020
Volume
159
Issue
1
Start / End Page
1 / 2
Location
United States
Related Subject Headings
- Uterine Neoplasms
- Oncology & Carcinogenesis
- Humans
- Female
- EGF Family of Proteins
- Cystadenocarcinoma, Serous
- Cohort Studies
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences